Headinvest buys $4,855,603 stake in C R Bard Inc (BCR)

C R Bard Inc (BCR) : Headinvest scooped up 2,010 additional shares in C R Bard Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 11, 2016. The investment management firm now holds a total of 21,348 shares of C R Bard Inc which is valued at $4,855,603.C R Bard Inc makes up approximately 1.73% of Headinvest’s portfolio.

Other Hedge Funds, Including , Ct Mason boosted its stake in BCR in the latest quarter, The investment management firm added 1,086 additional shares and now holds a total of 23,135 shares of C R Bard Inc which is valued at $5,121,164. C R Bard Inc makes up approx 2.27% of Ct Mason’s portfolio. Lynch Associatesin sold out all of its stake in BCR during the most recent quarter. The investment firm sold 2,000 shares of BCR which is valued $442,720.

C R Bard Inc closed down -9.69 points or -4.26% at $217.76 with 8,47,035 shares getting traded on Tuesday. Post opening the session at $227.4, the shares hit an intraday low of $217.38 and an intraday high of $227.4 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, C R Bard Inc reported $2.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $2.17. The company had revenue of $873.50 million for the quarter, compared to analysts expectations of $847.53 million. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.10 EPS.

Many Wall Street Analysts have commented on C R Bard Inc. C R Bard Inc was Upgraded by Wells Fargo to ” Outperform” on Sep 16, 2016. Company shares were Reiterated by Deutsche Bank on Jul 27, 2016 to “Hold”, Firm has raised the Price Target to $ 240 from a previous price target of $234 .Company shares were Reiterated by Barclays on Jul 27, 2016 to “Equal Weight”, Firm has raised the Price Target to $ 235 from a previous price target of $224 .

C. R. Bard Inc. (Bard) and its subsidiaries are engaged in the design manufacture packaging distribution and sale of medical surgical diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular urology oncology and surgical specialty. The Company also has a product group of other products. The Company’s vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products fecal and urinary continence products urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs in addition to hemostats and surgical sealants.

Leave a Reply

C R Bard Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on C R Bard Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.